Co-crystals of diflunisal and isomeric pyridinecarboxamides – a thermodynamics and crystal engineering contribution by Évora, António O. L. et al.
Évora, António O. L. and Castro, Ricardo A. E. and Maria, Teresa M. R. 
and Silva, M. Ramos and ter Horst, J. H. and Canotilho, João and 
Eusébio, M. Ermelinda S. (2016) Co-crystals of diflunisal and isomeric 
pyridinecarboxamides – a thermodynamics and crystal engineering 
contribution. CrystEngComm, 18 (25). pp. 4749-4759. ISSN 1466-8033 , 
http://dx.doi.org/10.1039/c6ce00380j
This version is available at https://strathprints.strath.ac.uk/56947/
Strathprints is  designed  to  allow  users  to  access  the  research  output  of  the  University  of 
Strathclyde. Unless otherwise explicitly stated on the manuscript, Copyright © and Moral Rights 
for the papers on this site are retained by the individual authors and/or other copyright owners. 
Please check the manuscript for details of any other licences that may have been applied. You 
may  not  engage  in  further  distribution  of  the  material  for  any  profitmaking  activities  or  any 
commercial gain. You may freely distribute both the url (https://strathprints.strath.ac.uk/) and the 
content of this paper for research or private study, educational, or not-for-profit purposes without 
prior permission or charge. 
Any correspondence concerning this service should be sent to the Strathprints administrator: 
strathprints@strath.ac.uk
The Strathprints institutional repository (https://strathprints.strath.ac.uk) is a digital archive of University of Strathclyde research 
outputs. It has been developed to disseminate open access research outputs, expose data about those outputs, and enable the 
management and persistent access to Strathclyde's intellectual output.
1 
 
Co-crystals of diflunisal and isomeric pyridinecarboxamides ʹ a 
thermodynamics and crystal engineering contribution 
  
António O. L. Évora
a*
, Ricardo A. E. Castro
b
, Teresa M. R. Maria
 a
, M. Ramos Silva
 c
, J. H. ter Horst
d
, João 
Canotilho
b
 and M. Ermelinda S. Eusébio
a
 
a
 Department of Chemistry, University of Coimbra, 3004-535 Coimbra, Portugal 
b
 Faculty of Pharmacy, University of Coimbra, Portugal 
c Department of Physics, University of Coimbra, Portugal 
d 
EPSRC Centre for Innovative Manufacturing in Continuous Manufacturing and Crystallisation (CMAC), 
Strathclyde Institute of Pharmacy and Biomedical Sciences (SIPBS), Technology and Innovation Centre, 
University of Strathclyde, 99 George Street, Glasgow G1 1RD, U.K. 
 
To whom correspondence should be addressed. E-mail: antonio.evora@uc.pt Tel.: 
+351239854450  
 
ABSTRACT 
 
Diflunisal is an anti-inflammatory non-steroidal drug, class II of the Biopharmaceutical Classification System, 
that has recently been the subject of renewed interest due to its potential use in the oral therapy of familial 
amyloid polyneuropathy. In this work, a thermodynamic based approach is used to investigate binary 
mixtures (diflunisal + picolinamide) and (diflunisal + isonicotinamide) in order to identify solid forms 
potentially useful to improve the biopharmaceutical performance of this active pharmaceutical ingredient. 
Special emphasis is put on the research of co-crystals and on the influence of structural changes in the 
pyridinecarboxamide co-former molecules on co-crystal formation with diflunisal. The thermodynamic 
based methodology described by ter Horst et al. in 2010 indicates that the formation of co-crystals is 
thermodynamically feasible for both systems. The binary solid-liquid phase diagrams are built and allow 
identifying unequivocally the formation of co-crystals of diflunisal with each of the two isomers and also 
their stoichiometry: 1:1, (diflunisal:co-former) in the case of pyridine-2-carboxamide, picolinamide, and 
(2:1) for pyridine-4-carboxamide, isonicotinamide. Two binary eutectic mixtures, potentially relevant for 
pharmaceutical application, are also identified. Infrared spectroscopy allows the identification of the 
acidN-pyridine heterosynthon in the three co-crystals formed by diflunisal with the isomeric 
pyridinecarboxamides. However, the results differentiate clearly pyridine-2-carboxamide from pyridine-3-
carboxamide and pyridine-4-carboxamide which share similar crystalline arrangements at least in what 
concerns the supramolecular synthons. 
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1. Introduction 
Co-crystals 1-6 have been the subject of intense research in the last decade, due to 
their great potential for practical applications in several domains,7,8 especially when active 
pharmaceutical ingredients, APIs, are concerned 5, 9, 10. Pharmaceutical co-crystals, 
combining an API and an acceptable co-former, 11 have the potential for enhancing the 
physical properties of the API, positively impacting its solubility, stability, oral 
bioavailability and processability, without compromising its biological function 1, 9, 12-21. 
Thus, co-crystal research formation spurs interest from pharmaceutical industry, especially 
for those APIs whose oral bioavailability is solubility limited, classes II and IV of the 
Biopharmaceutical Classification System (BCS) 22. For this kind of drugs, besides co-
crystals, binary eutectic mixtures, for instance, are also relevant 23-26 due to their increased 
surface area and the potential for increasing dissolution rate. Therefore, the establishment 
of the binary solid-liquid phase diagrams of the API and the potential co-former is of 
considerable interest as it gives comprehensive information of the solid binary mixtures 
behavior. 
Diflunisal, DIF, Figure 1.a, BCS class II nonsteroidal anti-inflammatory drug, finds 
application in medical practice in oral formulations for the acute or long-term treatment of 
rheumatoid arthritis, osteoarthritis, or mild to moderate pain 27, and research is currently 
been carried out on its use in familial amyloid polyneuropathy 28. Pyridinecarboxamides 
such as nicotinamide, NA, and the isomeric picolinamide, PA, and isonicotinamide, INA, 
(Figure 1) are quite appealing as co-formers, CoF, for target compounds with carboxylic 
acid groups, as association through different supramolecular heterosynthons can occur, 
envisaging the possibility of formation of co-crystals of different stoichiometry 29. In a 
previous study carried out by this research team on the DIF + NA system, a 2:1 co-crystal 
was identified 30, 31, and the presence of the acidN-pyridine heterosynthon in the co-
crystal structure was confirmed. Wang et al. 32 obtained a 2:1 DIF + NA co-crystal from 
equimolar ethanol solutions, and in the same experimental conditions a 2:1 DIF + INA co-
crystal. PA and INA differ from nicotinamide just on the amide group position relatively to 
the ring nitrogen (ortho, para, meta, respectively in PA, INA and NA). The proximity 
between the amide hydrogen and the heterocyclic nitrogen in PA, enabling intramolecular 
hydrogen bonding, has been regarded to contribute to a lower ability of PA to co-crystal 
formation 33, 34.  
Thermodynamic and crystal engineering principles are of fundamental relevance in 
order to control and predict crystallization process outcomes and co-crystal properties. 
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Some work has been published concerning the use of solubility measurements and ternary 
phase diagrams for co-crystal formation prediction and for design of rational preparative 
procedures from solutions30, 34-38. A systematic study of co-crystal formation in series of 
structurally related co-formers will contribute to the identification of thermodynamic and 
crystal engineering principles for co-crystal production and application.  
The current work therefore follows our interest in diflunisal multicomponent 
systems 11, 30, 31, and on the different pyridinecarboxamides as co-formers 34, 39: a 
thermodynamic based approach, including binary and ternary solid-liquid phase diagram 
establishment, is used in order to investigate solid forms for potential improvement of 
physical and chemical properties of the API. The influence of structural changes in the 
pyridinecarboxamide co-former molecules on co-crystal formation with diflunisal is 
discussed. 
 
a) 
 
 
 
 
b) c) d) 
 
FIGURE 1. Molecular structure a) Diflunisal; b) Picolinamide (pyridine-2-carboxamide) c) Nicotinamide 
(pyridine-3-carboxamide); d) Isonicotinamide (pyridine-4-carboxamide). 
 
2. Experimental 
2.1 Materials and mixtures preparation 
The starting materials were supplied by Aldrich with specified purify 0.99. XRPD 
confirmed diflunisal as the triclinic polymorph I 40, and picolinamide as polymorph II 41, 42. 
The room temperature thermodynamic stable isonicotinamide polymorph II (reference 
code EHOW1H01) 43-46 was used in this work experiments. For the preparation of mixtures 
of different composition the appropriate amounts of each substance were weighted in a 
Mettler balance M163 ( ± 0.01 mg) and then  mixed in a Retsch MM 400 ball mill, in 10 
mL stainless steel jars with two 7 mm stainless steel balls, for 30 minutes at a 15 Hz 
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frequency. For diflunisal + picolinamide, grinding was assisted by ethanol (10 µl), in most 
experiments, and for diflunisal + isonicotinamide neat grinding was carried out. Similar 
grinding experiments performed on the pure materials result in conversion of diflunisal 
from form I to form III 40 in ethanol assisted grinding experiments 30, while no changes 
were observed relatively to pure components¶ starting solid forms in all other experiments 
(results confirmed by XRPD). 
 
2.2 Co-crystal screening  
Crystal16 equipment by Avantium Technologies was used in order to determine saturation 
temperatures of pure components in ethanol and of mixtures of diflunisal with 
isonicotinamide or picolinamide in the same solvent. The equipment allows measuring 
cloud and clear points, based on turbidity, of sixteen 1 mL solution aliquots in parallel and 
automatically. The clear point temperature is the temperature at which a suspension 
becomes a clear solution upon slowly heating. The clear point temperature upon heating 
solution aliquots of beforehand established composition at a 0.3 K·min-1 temperature 
scanning rate was determined and taken as the saturation temperature of the used 
composition. The significance in the clear point temperatures of a single sample was less 
than 2°C in subsequent measurements. 
Ethanol was used, as it is a solvent of choice in pharmaceutical development: it belongs to 
class 3 of the residual solvents classification (low toxic potential) 42, 43, allowing also to 
achieve adequate drying of the solid samples at low temperatures. 
 
2.3 Differential scanning calorimetry(DSC) 
The studies were performed on a PerkinElmer Pyris1 power compensation calorimeter 
with an intracooler cooling unit at 248 K (ethylene glycol + water, 1:1 (v/v), cooling 
mixture). The samples, mass ׽2 mg, were hermetically sealed in 30 ȝL aluminum pans, 
and an empty pan was used as reference. A 20 mL·min-1 nitrogen purge was employed. 
Scanning rates ȕ = 10 K·min-1 and ȕ = 2 K·min-1 were used. Temperature calibration 47, 48 
was performed with the high-grade standards: biphenyl (CRM LGC 2610, Tfus= (342.08 ± 
0.03) K), benzoic acid (CRM LGC 2606, Tfus= (395.50 ± 0.02) K), indium (Perkin-Elmer, 
x = 0.9999, Tfus= 429.75 K), and caffeine (Mettler Toledo calibration substance, ME 18 
872, Tfus = (509.75 ± 0.2) K). Enthalpy calibration was performed with indium (ǻfusHm = 
3286 ± 13 J·mol-1) 47 and verified with the fusion enthalpy of biphenyl (ǻfusHm = 18574 ± 4 
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J·mol-1)47 and benzoic acid (ǻfusHm = 18063 ± 42 J·mol-1)47.  The uncertainties of the 
measurements are estimated to be ± 0.2 K for temperature and ± 2 % for enthalpy.  
 
2.4 Infrared spectroscopy (FTIR) 
The IR spectra were collected, with 1 cm-1 spectral resolution, on a ThermoNicolet 
IR300 Fourier transform infrared spectrometer, equipped with a deuterated triglycine 
sulfate (DTGS) detector and a Ge/KBr beam splitter, using the KBr pellet technique. 
 
2.5 X-ray Power diffraction (XRPD) 
A Bruker-AXS D2 Phaser X-ray powder diffractometer, Bragg-Brentano geometry, was 
used with Ni-filtered Cu KĮ,(Ȝ Å) radiation and a Lynxeye detector. A rotating 
glass capillary ENRAF-NONIUS powder diffractometer, equipped with a CPS120 detector 
by INEL, was also employed with data collection in Debye-Scherrer geometry, using 
monochromatized CuKĮ1 radiation (Ȝ = 1.540598 Å). Silicon was used as an external 
calibrant. 
 
3. Results and discussion 
3.1 Co-crystal screening 
The ability of co-crystal formation of diflunisal (DIF) with isonicotinamide (INA) 
and picolinamide (PA) is confirmed by applying the methodology described by ter Horst et 
al. 34, 37, using clear point temperature measurements of suspensions in ethanol. In a first 
step of this procedure, the solubility of the pure compounds in ethanol was determined. 
The saturation temperatures obtained for different solution concentrations could be well 
correlated to the simplified van´t Hoff equation (1) as shown in Figure 2.  
  D? ൌ െ ȟD? D?ሺ ? D? െ  ? D?଴ ? ሻ ?      (1) 
 
The variables 'H/R and 'H/RT0 are used as fitting parameters and their fitted values are 
presented in table 1. For the co-formers the solubilities are in good agreement with what 
was previously obtained by ter Horst et al. 37. XRPD confirms DIF form III as the solid 
phase in equilibrium with the solutions and for the co-formers INA, form I (contaminated 
with form II) and PA form II were obtained (Figure S1, supplementary material).  
In a second step, the saturation temperatures, Ts, of mixtures of composition (xDIF*,xCoF*) 
are determined after dissolution and recrystallization, using ethanol as the solvent. The 
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pure component saturation concentrations xDIF* and xCoF* were interpolated or extrapolated 
from the van´t Hoff fitting, both at a reference temperature Tref. The resulting saturation 
temperatures Ts are compared with the reference temperatures, Tref, used to make the 
sample composition (xDIF*,xCoF*). If diflunisal and the co-formers are able to form a stable 
co-crystal, then the Ts of the co-crystal in the mixed solutions should be higher than the Tref 
37
. This was observed in both cases as shown in Figure 3, where data for NA 30 were also 
included.  
The observed temperature differences (TS-Tref) are very high, above 48K for all 
three systems. This large temperature difference indicates not only that co-crystal 
formation is highly likely, but also that the resulting co-crystals are very stable. In the X-
ray powder diffractograms of the obtained recrystallized solids after the saturation 
temperature measurements, new reflections are further evidence that a new solid entity is 
formed (Figure S2, supplementary material).  
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TABLE 1. Parameters of WKHYDQ¶W Hoff equation for diflunisal, isonicotinamida and picolinamide 
and for the co-crystals DIF + INA and DIF + PA, in ethanol.  
 
 
ሺȟD? D? ? ሻ / K ȟD? D?D?଴ ?  
DIF (2.4 ± 0.1 ) x103 4.3 ± 0.2 
INA (2.8 ± 0.1 ) x103 6.0 ± 0.2 
PA (3.9 ± 0.1 ) x103 10.1 ± 0.3 
DIF : INA (6.4 ± 0.3 ) x103 11 ± 1 
DIF : PA (8.3 ± 0.3 ) x103 17 ± 1 
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FIGURE 3. Temperature difference (Ts - Tref) between the measured saturation temperature Ts of 
samples of composition (xDIF*(Tref), xCoF*(Tref)), versus Tref. The mole fractions xDIF*(Tref) and 
xCoF*(Tref) indicate the solubility of respectively DIF and CoF at the reference temperature Tref. (ź) 
DIF + NA 30; (ż) DIF + INAƑDIF + PA. 
 
 
)URP WKH YDQ¶W +RII plots shown in Figure 2 for DIF:INA and DIF:PA in ethanol, the 
parameters presented in Table 1 were obtained. These were used to draw estimates of the 
isothermal ternary phase diagrams for DIF:INA and DIF:PA in ethanol at 298 K and 323 
K, Figure 4. Both co-crystals are very stable and may be obtained by addition of small 
amount of the co-formers to the API saturated solutions. The composition of the 3-phase 
equilibrium points shown in Figure 4 for the DIF+INA+ethanol system are (xDIF = 7.6x10-4; 
xINA = 3.3x10
-2) and (xDIF = 2.4x10-2; xINA = 1.1x10-3), at 25 ºC and (xDIF =1.9x10-3; xINA 
=7.0x10-2) and (xDIF = 4.4x10-2; xINA = 3.1x10-3) at 50 ºC. For DIF+PA+ethanol the 
corresponding values are (xDIF = 2.4x10-4; xPA = 5.2x10-2) and (xDIF = 2.4x10-2; xPA= 5.3x10-4 
), at 25 ºC and (xDIF =7.3x10-4; xPA =1.4x10-1) and (xDIF = 4.4x10-2; xPA = 2.4x10-3) at 50 ºC. 
From the phase diagram it is apparent that the compositional region for obtaining co-
8 
 
crystal is very large: there is thus a large freedom in the choice for solution composition 
during co-crystal production. 
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FIGURE 4. Estimated isothermal ternary phase diagrams for a) DIF+PA and b) DIF+INA in 
ethanol at 298 and 323 K. The curved part of the lines gives co-crystal solubility. 
 
 
 
3.2 (Solid +  liquid) binary phase diagrams 
Binary (solid + liquid) phase diagrams are conclusive evidence of co-crystal or salt 
formation, allowing the determination of their stoichiometry. Salt formation is not 
expected for the systems under investigation due to the pKa differences between the 
components: 'pKaINA-DIF = 0.4; 'pKaPA-DIF = -1.4 20, 23, 24, 49, 50. Additionally, from these 
diagrams, other mixture compositions, such as the binary eutectic mixtures, which may 
also be of interest in pharmaceutical formulations due to their potential increased 
dissolution rate, can also be identified 24-26, 30, 51, 52In the construction of binary (solid + 
liquid) phase diagrams for (DIF + INA) and (DIF + PA) systems, DSC measurements on 
mixtures of different composition prepared by grinding were performed.  
 
 
Diflunisal + isonicotinamide 
 
Illustrative DSC thermograms obtained for different mixtures of DIF + INA are presented 
in Figure 5. 
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FIGURE 5. DSC heating curves for selected DIF + INA mixtures at a heating rate ȕ = 2 K min-1. 
1. xDIF = 0; 2. xDIF = 0.0502; 3. xDIF = 0.1667; 4. xDIF = 0.1999; 5. xDIF = 0.2501; 6. xDIF = 0.4004; 7. 
xDIF = 0.6667; 8. xDIF = 0.7484; 9. xDIF = 0.7996; 10. xDIF = 0.8572; 11. xDIF = 1.000. *- 
isonicotinamide ,,ĺ, transition. 
 
 
A single narrow peak is observed in the thermogram of the xDIF = 0.6667 mixture, as 
expected for a 2:1 DIF:INA co-crystal, with melting temperature Tfus = (452.2 ± 0.3) K and 
DKHDWRIIXVLRQ¨fusHm = ( 88.6 ± 1.8) kJ·mol-1, averaged over n = 6 experiments.  
In the DSC curves for mixtures that contain an excess of the co-former, xDIF < 0.6667, two 
invariant points at TE1 = (406.3 ± 2.2) K and TE2 = (412.3 ± 0.6) K are observed. These are 
ascribable to two eutectic points involving different INA polymorphs and the co-crystal. 
INA form II, the starting material, has a solid-solid phase transition on heating, Figure 5, 
curve 1 (marked by a *), giving rise to form I, as already described in literature 45 and 
confirmed in our laboratory. The form I melting temperature is Tfus = (428.7 r 0.5) K and 
KHDWRIIXVLRQ¨fusHm = (22.9 r 0.5) kJmol-1. For xDIF > 0.6667, figure 5, a new invariant 
point is observed at TE3 = (450.4 ± 1.3) K. 
The binary solid-liquid phase diagram for (DIF + INA) derived from DSC data is shown 
on Figure 6. The solidus curve in the diagram is obtained from the onset temperature, TE, 
of the first peak and the liquidus curve from the peak temperature, Tliq, of the last peak 
observed in each DSC thermogram 53, 54.  Maximum uncertainties on the temperature 
values are r 0.8 %. These results are shown in table S1 for (diflunisal + isonicotinamide). 
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10 K·min-1); solid lines are used as guides for the eye; dotted  lines represent  ideal behavior. 
 
The enthalpies of fusion of the eutectic peaks in the DSC curves of mixtures of different 
compositions were used to construct the triangular Tammann plots shown in Figure 7. 
Tammann plots are normally used in order to define the eutectic compositions and to 
evaluate the possibility of solid solution formation.51, 55 The enthalpy values used in Figure 
7 were obtained by deconvolution of the complex DSC curves registered at  
ȕ = 2 K·min-1(Uncertainties in these enthalpy values are at maximum r 5%).  For mixtures 
with xDIF  , Figure 7.a, the sum of the enthalpies of both invariant temperature 
peaks at TE1~ 406 K and TE2 ~ 412.3 K was used. The fitted straight lines defining the 
Tammann triangle, Figure 7.a, intercept the composition axis at xDIF = 0 and xDIF = 0.6667 
(the exact co-crystal composition) as expected if no solid solutions are formed (otherwise 
zero eutectic melting enthalpy will be observed at other composition). The eutectic 
composition is found at the apex of the triangle as xDIF = 0.20. For mixtures with xDIF  
0.6667, Figure 7.b, the enthalpy of the invariant temperature peaks at TE3 ~ 450 K was 
used. The eutectic composition is too close to the co-crystal composition and from the data 
it is not possible to obtain a precise value. The Tammann plot gives evidence of the 
expected evolution of the enthalpy of fusion of the eutectic mixture as diflunisal content 
increases. No evidence of solid solution formation is found for diflunisal rich mixtures 
(interception of the straight line with the composition axis at xDIF = 1). 
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FIGURE 7. Tammann plots for the (diflunisal + isonicotinamide) system a. xDIF b. xDIF 
0.6667. 
 
Assuming complete immiscibility in the solid phase and total miscibility in the 
liquid one, and that the enthalpy of fusion does not change in the temperature range 
considered, the liquidus temperatures Tfus,i* for compositions where an excess of a pure 
component i is present can be calculated using eq.(2)56. ଵ்I?I?I?ൌ ଵ்I?I?I?ǡI?כ െ ோ୼I?I?I?ுI?ǡI?כ  D?௜D?௜,    (2) 
 
Tfus is the liquidus temperature of a mixture of mole fraction xi of component i, whose 
fusion temperature and molar enthalpy of fusion, when pure, are Tfus,i* DQG ǻfusHm,i*, 
respectively, and Ȗi is the activity coefficient of i in the liquid solution. Taking Tfus,DIF* = 
   . DQG ¨fusHm,DIF* = (35.6 ± 1.0) kJ·mol-1, the activity coefficients of 
diflunisal were calculated and the values found to range from ȖDIF = 0.90 for xDIF  = 0.8988 
to ȖDIF = 0.76 for xDIF  =  0.7484, reflecting a negative deviation from ideal behavior, 
indicating significant intermolecular interactions between both compounds in the liquid 
phase. In the isonicotinamide rich region of the diagram the deviation from ideality is 
much lower with ȖINA = 0.99 for xDIF  = 0.0502 and ȖINA = 0.98 for xDIF  = 0.1667 (Tfus,INA* = 
 .DQG¨fusHm,INA* = ( 22.9 ± 0.5) kJ·mol-1 were used in the calculations). 
Ideal behaviour was calculated, for diflunisal compositions between both eutectic points, 
using equation (3) 56, with the experimental fusion data for the co-crystal, Tfus,DIF:INA and 
ǻfusHm,DIF:INA, 
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Ideal behavior is represented in Figure 6 by the dotted lines. 
 
 
Diflunisal + picolinamide 
 
The DSC curves shown in Figure 8 for (DIF + PA) mixtures of different composition show 
a different behavior for mixtures of compositions higher and lower than xDIF = 0.50. For 
xDIF = 0.50 a single narrow peak is observed at Tfus = (459.7 ± 0.2) K with melting enthalpy 
¨fusHm = ( 65.8 ± 2.2) kJ·mol-1, n = 8, indicating  a 1:1 co-crystal formation. 
 
FIGURE 8.  DSC heating curves for selected DIF + PA mixtures, ȕ = 2 K min-1. 1. xDIF = 0; 2. xDIF 
= 0.1636; 3. xDIF = 0.3334; 4. xDIF = 0.3996; 5. xDIF = 0.5000; 6. xDIF = 0.5569; 7. xDIF = 0.6061; 8. 
xDIF = 0. 6557; 9. xDIF = 0.7492; 10. xDIF = 0.8547; 11. xDIF = 0.8954; 12. xDIF = 0.8990; 13. xDIF = 
1.000. 
 
The polymorphism of picolinamide is clearly evident in the DSC curves for mixtures with 
an excess of this substance. Picolinamide, polymorph II, may experiment a solid-solid 
phase transition to form I in the heating process at T ~350 K (Figure 8, curve 1) and 
melting of I occurs at Tfus,I = (379.6 ± 0.4) K 41. In some experiments, fusion of form II can 
be observed, Tfus,II = (375.2 ± 0.4) K, with subsequent crystallization of form I from the 
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liquid and melting of I 41. The two invariant temperatures registered in the DSC curves of 
mixtures (DIF + PA), xDIF < 0.50, TE1 = (373.6 ± 0.4) K and TE2 = (377.7 ± 0.4) K, are 
ascribable to eutectic mixtures containing picolinamide polymorphs II and I, respectively.  
Another invariant temperature is observed at TE3 = (453.4 ± 0.9) K, for xDIF > 0.50, which 
is assigned to the eutectic point for the co-crystal and DIF. For xDIF > 0.5, mixtures were 
prepared both by ethanol assisted grinding, EAG, and by neat grinding. For these 
compositions, DSC curves of EAG mixtures present a more complex profile when 
compared to neat prepared ones, as exemplified by curves 11 and 12 in Figure 8. This 
results from the transition, at least in part, of diflunisal polymorph III to form I.  
The binary solid-liquid phase diagram of pyridine-2-carboxamide, picolinamide, 
and diflunisal, derived from DSC curves, is shown in Figure 9. Maximum uncertainties on 
the temperature values are r 0.8 %. 
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Figure 9. 6ROLGOLTXLGSKDVHGLDJUDPRI',)3$ƔR eutectic temperature, Ÿ¨, liquidus 
WHPSHUDWXUH Ŷ SXUH FRPSRXQG IXVLRQ VROLG V\PEROV ȕ = 2 K·min-1, empty symbols, ȕ = 10 
K·min-1); solid lines are used as guides for the eye; dotted lines represent ideal behavior 
 
It is worth noting that the first eutectic point lies at a composition of almost pure 
picolinamide. This indicates a very stable co-crystal compared to pure picolinamide. The 
composition of the eutectic mixture, melting at TE3 ~ 453 K, is estimated to be xDIF = 0.65 
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from the Tammann plot shown in Figure 10 (Uncertainties in these enthalpy values are at 
maximum r 5%).  There is no evidence of solid solution formation both in the vicinity of 
the co-crystal and of pure diflunisal. 
 
FIGURE 10. Tammann plot for the (diflunisal + picolinamide) system, xDIF 5000.  
 
The binary solid-liquid phase diagram of (DIF + Pa) shows negative deviation from ideal 
solution (dotted lines in Figure 9). Equation (4), a modification of equation (3) taking into 
account the stoichiometry of this particular co-crystal, was used to calculate ideal liquidus 
temperatures in the neighborhood of the co-crystal, between the two eutectic points.  
 ଵ்I?I?I?ൌ ଵ்I?I?I?ǡ	ǣെ ோ୼I?I?I?ுI?ǡ	ǣ ሼሾD?	  ?ሺ ? െ D?	ሻሿ െ   ?Ǥ ? ?ሽ  (4) 
 
Values that range from ȖDIF = 0.97 for xDIF  = 0.9357 to ȖDIF = 0.87 for xDIF  =  0.7482, are 
obtained, from eq.(2), for mixtures richer in diflunisal, indicating also in this system, 
solution negative deviation from ideal behavior (dotted line in Figure 9). However, 
deviations from ideality are much lower in this system than for (DIF + INA) system, 
reflecting lower intermolecular between DIF and PA in the molten phase. 
 
3.3 XRPD and FTIR characterization 
The XRPD data presented in Figures 11.a and 11.b for the (diflunisal + isonicotinamide) 
and (diflunisal + picolinamide) systems, respectively, clearly identifies new solid state 
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arrangements for the co-crystals, with new reflections when compared to the pure 
component patterns.  
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Figure 11. X-ray powder diffractograms  a. DIF + INA: 1. DIF, polymorph I; 2. INA, polymorph 
II; 3. Co-crystal xDIF = 0.6667; 4. xDIF = 0.3323 (INA II excess, blue dashed lines); 5. xDIF = 0.8572 
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(DIF I excess, red dashed lines). b.  DIF + PA: 1. DIF, polymorph III; 2. PA, polymorph II; 3. Co-
crystal xDIF = 0.5000; 4. xDIF = 0.3334 (PA II excess, blue dashed lines); 5. xDIF = 0.6654 (DIF III 
excess, red dashed lines ).  
 
In addition, peaks corresponding to the presence of the excess components are clearly 
seen in figure 12.a for xDIF = 0.3323 - INA II excess, 2ș = 17.8, 18.8, 19.4, 20.8, 23.5, 
26.6and 30.9 º - and xDIF = 0.8572 ± DIF I excess, 2ș = 12.4, 16.6, 17.1, 23.8, 26.7, 
28.3,and 28.8º. A similar analysis can be made in figure 12.b for xDIF = 0.3334 - PA II 
excess, 2ș = 18.8, 20.8, 21.1, 21.4, 25.5 and 28.4º - and xDIF = 0.6654 - DIF III excess, 2ș 
= 14.4, 15.5, 24.6, 25.9 and 27.0º. A similar comparison is made, in Figures S3 to S5 
(supplementary material) using infrared spectra. XRPD data indicates that the (2:1) 
diflunisal-isonicotinamide co-crystal synthesized in the current work is the same identified 
recently by Wang et al. 32  
The FTIR spectra of the co-crystals formed by each of the three pyridinecarboxamide 
isomers and diflunisal are presented in Figure 12.  
 The heterosynton formed by acid-Naromatic groups is identified in the three co-
crystals by the characteristics bands at about 2500, 2150 and 1900 cm-1 26, 57-60. There is a 
reduced number of co-crystals reported in literature using picolinamide as a co-former 33, 
39
. In this isomer, the aromatic nitrogen, ortho relatively to the amide group, is, a priori, 
less prone to be involved in intermolecular interactions. However, it was observed that the 
aromatic nitrogen participates in Namide-+«1aromatic bonds in the crystal lattice of the 
picolinamide:salycilic acid co-crystal and also in the acid O-+«1aromatic bond in the co-
crystal of picolinamide with adipic acid 33. The infrared spectrum obtained in the current 
work points out to picolinamide association with diflunisal involving this latter 
heterosynthon.  
However, in the NH2 elongation region, significant differences are observed between 
the spectrum of the diflunisal:picolinamide co-crystal and those formed by diflunisal and 
the 3- and 4-pyridinecarboxamide isomers. 7KH DV\PPHWULF HORQJDWLRQ EDQG Ȟas(NH2), 
appears at 3372 cm-1 and at 3367 cm-1, in INA and in NA, respectively, and in the co-
crystals it is shifted to higher energies: 3394 cm-1 for DIF:INA co-crystal and 3406 cm-1 
for DIF:NA. A similar behaviour is observed for the symmetric elongation mode, Ȟs(NH2): 
3176 cm-1 in INA and 3209 cm-1 in the co-crystal DIF:INA, 2:1; 3162 cm-1 in nicotinamide 
and 3229 cm-1 in the co-crystal DIF:NA, 2:1. This blue shift behavior was reported by 
Desiraju et al 31 in the formation of cyclic acid-amide heterodimers and proposed as a 
marker to identify this synthon in co-crystals. 
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FIGURE 12. FTIR spectra of the co-crystals: 1. DIF + INA (2:1); 2. DIF + PA (1:1); 3.  DIF + NA 
(2:1) 30. 
 
 
 In contrast, the IR spectra of the DIF:PA co-crystal are substantially different from 
those of DIF:INA and DIF:NA. In the DIF:PA co-crystal the asymmetric, Ȟas(NH2), and the 
symmetric, Ȟs(NH2), elongation modes are redshifted when compared to picolinamide 
spectrum: Ȟas(NH2) and Ȟs(NH2) have their maxima at 3417 and 3176cm-1, respectively, in 
picolinamide, form II, which are shifted to 3394 cm-1 and 3106 cm-1 in the co-crystal. 
Desiraju et al.,60 in their attempt to identify synthons in co-crystals and polymorphs using 
infrared spectroscopy, with a special focus on primary amides, associate deviations of NH2 
elongations frequencies to lower energies to the change in association from dimers to 
chains. Centrosymmetric amide±amide dimers are present in the crystalline structure of 
picolinamide. From the co-crystal infrared spectrum, and taking into account Desiraju et 
al. conclusions, the change to chain association is quite plausible.   
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The results show that, although co-crystals have been obtained for diflunisal with the three 
isomeric pyridinecarboxamides, the structural differences of the co-formers have an 
important influence in the supramolecular association, clearly distinguishing pyridine-2-
carboxamide from the others. 
 
3.4 Crystallization experiments 
The ternary phase diagrams DIF-CoF-ethanol, Figure 4, were used to design co-
crystallization experiments in order to obtain the pure co-crystals. Solutions of appropriate 
composition were prepared at 323 K and then cooled to 298 K. The used solution 
compositions were chosen in the region marked by A in the diagrams ± below line a-b that 
joins the pure components solubility at 298 K and also below the co-crystal solubility at 
323 K. This procedure allowed the preparation of pure samples of the co-crystals described 
in this work as confirmed by XRPD and FTIR.    
Data presented in Figure 4, combined with the known co-crystals stoichiometry, allow 
the construction of the complete triangular ternary phase diagrams, at T = 298 K, presented 
in Figures 13 and 14. Pure co-crystals can also be obtained starting from solution (region 4 
in the diagram) and evaporating the solvent, at constant temperature, until region 1 is 
reached. 
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FIGURE 13. Ternary phase diagram of diflunisal-isonicotinamide-ethanol at T = 298 K. 
equilibrium phases in the diagram: 1. co-crystal+liquid; 2. INA+co-crystal+liquid; 3. DIF+co-
crystal+liquid; 4. liquid; 5. INA+liquid. 
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FIGURE 14. Ternary phase diagram of diflunisal-picolinamide-ethanol at T = 298 K. 
equilibrium phases in the diagram: 1. co-crystal+liquid; 2. PA+co-crystal+liquid; 3. DIF+co-
crystal+liquid; 4. Liquid. 
 
 
Although the pure co-crystals were generated in the co-crystallization processes 
designed by the ternary phase diagrams, powder samples were always obtained. No single 
crystals, suitable for structure determination, could be produced, which, unfortunately, is 
not uncommon in the synthesis of co-crystals.  
Subsequent experiments carried out in order to obtain single crystals of the two 
identified co-crystals were unsuccessful: crystallization from various solvents, methanol, 
1-butanol, acetone, ethyl acetate, ethyleneglycol diethylether, tetrahydrofuran, acetonitrile, 
dimethylsulfoxide, p-xylene, with supersaturation achieved in different ways, and also with 
seeding with the  co-crystals obtained by grinding was tried; crystallization from gel media 
was also tested61.  
 
 
4. Conclusions 
 
The thermodynamic approach used in the current work successfully predicts co-
crystal formation between diflunisal and  picolinamide and isonicotinamide, as it was 
found before for the other pyridinecarboxamide isomer, nicotinamide30 and despite the 
differences of the co-former molecular structures. The solid-liquid binary phase diagrams 
give conclusive evidence of co-crystals formation and of their stoichiometry: a (1:1) co-
crystal with picolinamide, and a (2:1) co-crystal with isonicotinamide. The determined 
ternary phase diagrams enable the design of co-crystallization processes. 
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Differences in the association between pyridine-2-carboxamide and diflunisal 
relatively to the other two pyridinecarboxamide isomers are clearly evidenced by the 
infrared spectra. In opposition to pyridine-3-carboxamide and pyridine-4-
carboxamide:diflunisal co-crystals, which share significant structural similarities, at least 
in what concerns the supramolecular synthons, different heterosynthons involving the NH2 
group are expected in the diflunisal + pyridine-2-carboxamide co-crystal.  
Two binary eutectic mixtures, potentially relevant for pharmaceutical applications, are 
identified from the solid-liquid binary phase diagram investigations (DIF:INA, xDIF = 0.20 
and DIF:PA, xDIF = 0.65). 
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GRAPHICAL ABSTRACT 
 
Co-crystals of diflunisal and isomeric pyridinecarboxamides ʹ a 
thermodynamics and crystal engineering contribution  
António O. L. Évora,a*  Ricardo A. E. Castro,b Teresa M. R. Maria, a M. Ramos Silva, c  J. 
H. ter Horst, d João Canotilhob and M. Ermelinda S. Eusébioa 
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+3 - Diflunisal+nicotinamide
2 - Diflunisal+picolinamide
1 - Diflunisal+isonicotinamide
Co-crystals
